Counselors in Cave Junction, OR Accepting Medicare
3 Counselors found. Showing 1 - 3
 Justin Harrison Lyons, CADC-I, QMHA-R Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 310 Gamay Dr, Cave Junction, OR 97523 Phone: 541-733-4249 |
Mr. Larry Bates Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 25647 Redwood Hwy, Cave Junction, OR 97523 Phone: 541-592-4111 Fax: 541-592-3916 |
 Anna Marie Aguilar Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 319 Caves Hwy, Cave Junction, OR 97523 Phone: 541-476-2373 |
News Archive
Market Media Connect retained as Northwest Biotherapeutics' communications agency of record
Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.
Optical and PET/CT activity-based probes could help in non-invasive imaging of atherosclerotic plaques
Researchers at Stanford University have demonstrated for the first time the use of a dual optical and PET/CT activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of the Journal of Nuclear Medicine.
Very low birth weight infants do not receive optimal nursing care, finds study
Very low birth weight infants, those weighing less than 3.25 pounds, account for half of infant deaths in the United States each year, yet a new study released in today's issue of JAMA-Pediatrics documents that these critically ill infants do not receive optimal nursing care, which can lead to hospital-acquired infections that double their death rate and may result in long-term developmental issues affecting the quality of their lives as adults.
Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia
Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
Research: Algae's natural sunscreen molecules absorb UVA and UVB radiation with high efficiency
For consumers searching for just the right sunblock this summer, the options can be overwhelming. But scientists are now turning to the natural sunscreen of algae - which is also found in fish slime - to make a novel kind of shield against the sun's rays that could protect not only people, but also textiles and outdoor materials.
› Verified 2 days ago